Plain-English translation of NCT06288633 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing cardioneuroablation, a procedure that uses radiofrequency energy delivered through a thin catheter to gently damage specific nerve clusters in the heart. The goal is to help the heart beat faster in people with severe bradycardia (abnormally slow heart rate) and repeated fainting episodes. Researchers believe this treatment might work as an alternative to implanting a permanent pacemaker in some patients.
Many people with severe slow heart rhythms currently need a permanent pacemaker, which requires surgery and lifelong device management. This trial is exploring whether a less invasive nerve-modifying procedure could achieve similar results without the need for an implanted device.
You likely qualify if…
You likely don't qualify if…
If you qualify and are enrolled, you will undergo a catheter procedure performed under local anesthesia at a hospital. Half of participants will receive cardioneuroablation (radiofrequency energy applied to nerve clusters in the heart), while half will receive a sham procedure (the study is blinded so you won't know which). The procedures are similar in what participants experience. You will be monitored during and after the procedure, and follow-up visits will track how your heart rhythm responds to this treatment over time.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
Russia
Sponsor
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Collaborators
Meshalkin National Medical Research Center, Ministry of Health of Russian Federation, The Federal Centre of Cardiovascular Surgery, Russia
Enrollment target
~106 participants
Started
March 2024
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in March 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Aleksandr Vakhrushev, PhD
Almazov National Medical Research Centre
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.